亚胺培南-西司他丁-瑞来巴坦用于耐多药革兰氏阴性菌感染的早期多中心经验
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.
作者信息
Rebold Nicholas, Morrisette Taylor, Lagnf Abdalhamid M, Alosaimy Sara, Holger Dana, Barber Katie, Justo Julie Ann, Antosz Kayla, Carlson Travis J, Frens Jeremy J, Biagi Mark, Kufel Wesley D, Moore William J, Mercuro Nicholas, Raux Brian R, Rybak Michael J
机构信息
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina, USA.
出版信息
Open Forum Infect Dis. 2021 Dec 9;8(12):ofab554. doi: 10.1093/ofid/ofab554. eCollection 2021 Dec.
Abstract
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.
摘要
一项多中心病例系列研究中，21例患者接受了亚胺培南-西司他丁-雷利巴坦治疗。感染源混合多样，其中肺部感染占多数（11/21，52%）。主要病原体为[此处原文缺失病原体信息]（16/21，76%），且16株中有15株（94%）为多重耐药菌。21例患者中有14例（67%）存活30天。2例患者出现不良反应。
相似文献
1
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.亚胺培南-西司他丁-瑞来巴坦用于耐多药革兰氏阴性菌感染的早期多中心经验
Open Forum Infect Dis. 2021 Dec 9;8(12):ofab554. doi: 10.1093/ofid/ofab554. eCollection 2021 Dec.
2
Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.亚胺培南/西司他丁/雷巴他定：一种新的碳青霉烯β-内酰胺酶抑制剂组合。
Am J Health Syst Pharm. 2021 Mar 31;78(8):674-683. doi: 10.1093/ajhp/zxab012.
3
Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.雷利巴坦对假单胞菌来源头孢菌素酶 3（PDC-3）的抑制作用。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02406-17. Print 2018 May.
4
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.亚胺培南/瑞来巴坦和头孢洛扎/他唑巴坦对具有难治性耐药和多重耐药表型的革兰氏阴性杆菌临床分离株的体外活性——美国2015 - 2017年抗菌药物耐药趋势监测研究
Clin Infect Dis. 2021 Jun 15;72(12):2112-2120. doi: 10.1093/cid/ciaa381.
5
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.亚胺培南-西司他丁-瑞来巴坦：一种用于治疗多重耐药革兰氏阴性菌感染的新型β-内酰胺-β-内酰胺酶抑制剂组合。
Pharmacotherapy. 2020 Apr;40(4):343-356. doi: 10.1002/phar.2378. Epub 2020 Mar 9.
6
activity of imipenem-relebactam against resistant phenotypes of and isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.亚胺培南-雷巴坦对来自腹腔内和尿路感染样本的 和 耐药表型的活性-SMART 监测欧洲 2015-2017。
J Med Microbiol. 2020 Feb;69(2):207-217. doi: 10.1099/jmm.0.001142. Epub 2020 Jan 22.
7
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.头孢地尔优于亚胺培南西司他丁钠治疗革兰氏阴性尿路病原体引起的复杂性尿路感染：一项 2 期、随机、双盲、非劣效性试验。
Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.
8
Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.亚胺培南-雷巴他定对美国医院实验室分离的革兰氏阴性杆菌临床分离株的活性，这是 SMART 2016 计划的一部分。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00169-18. Print 2018 Jul.
9
In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.2015-2017 年美国 SMART 监测：重症监护病房下呼吸道感染患者样本中分离的革兰氏阴性杆菌对亚胺培南/雷巴他定和关键β-内酰胺类药物的体外活性。
Int J Antimicrob Agents. 2020 Jan;55(1):105841. doi: 10.1016/j.ijantimicag.2019.10.022. Epub 2019 Nov 6.
10
In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019.2016-2019 年，作为 CANWARD 研究的一部分，在加拿大各地的患者中分离出的肠杆菌科和铜绿假单胞菌的各种耐药表型/基因型对亚胺培南-雷巴他韦的体外活性。
Diagn Microbiol Infect Dis. 2021 Sep;101(1):115418. doi: 10.1016/j.diagmicrobio.2021.115418. Epub 2021 May 6.
引用本文的文献
1
Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.新型β-内酰胺/β-内酰胺酶抑制剂联合用药的临床疗效、安全性及药代动力学：一项系统评价
JAC Antimicrob Resist. 2025 Jun 19;7(3):dlaf096. doi: 10.1093/jacamr/dlaf096. eCollection 2025 Jun.
2
Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.突破耐药性：新型β-内酰胺酶抑制剂（阿维巴坦、瓦博巴坦、瑞来巴坦）抗多重耐药超级细菌的比较综述
Antibiotics (Basel). 2025 May 21;14(5):528. doi: 10.3390/antibiotics14050528.
3
Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study).亚胺培南-瑞来巴坦治疗难治性铜绿假单胞菌感染作为挽救疗法的真实世界经验（IMRECOR研究）
Infect Dis Ther. 2025 Jan;14(1):283-292. doi: 10.1007/s40121-024-01077-z. Epub 2024 Nov 29.
4
First case report of a vertebral osteomyelitis caused by carbapenem-resistant treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion.首例耐碳青霉烯类药物所致脊椎骨髓炎的病例报告，先采用亚胺培南/西司他丁/瑞来巴坦延长输注治疗，后改为美罗培南/伏巴拉坦持续输注。
Front Pharmacol. 2024 Oct 30;15:1347306. doi: 10.3389/fphar.2024.1347306. eCollection 2024.
5
Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing complex and difficult-to-treat resistance (DTR) infections: a single-center preliminary experience.亚胺培南/西司他丁/瑞来巴坦在治疗产KPC的复杂且难治性耐药（DTR）感染中的真实世界应用：单中心初步经验
Front Microbiol. 2024 Jul 16;15:1432296. doi: 10.3389/fmicb.2024.1432296. eCollection 2024.
6
Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence.亚胺培南/西司他丁/瑞来巴坦用于复杂性感染：真实世界证据
Life (Basel). 2024 May 10;14(5):614. doi: 10.3390/life14050614.
7
Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis.亚胺培南/瑞来巴坦对革兰氏阴性杆菌的全球耐药性：系统评价和荟萃分析
Curr Ther Res Clin Exp. 2023 Oct 28;100:100723. doi: 10.1016/j.curtheres.2023.100723. eCollection 2024.
8
Severe infections caused by difficult-to-treat Gram-negative bacteria.严重的感染由难以治疗的革兰氏阴性菌引起。
Curr Opin Crit Care. 2023 Oct 1;29(5):438-445. doi: 10.1097/MCC.0000000000001074. Epub 2023 Jul 31.
9
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.RESTORE-IMI 2临床试验中参与者及疾病相关因素作为治疗结果的独立预测因素：多变量回归分析
Open Forum Infect Dis. 2023 May 4;10(6):ofad225. doi: 10.1093/ofid/ofad225. eCollection 2023 Jun.
10
Novel Antimicrobial Agents for Gram-Negative Pathogens.用于革兰氏阴性病原体的新型抗菌剂。
Antibiotics (Basel). 2023 Apr 16;12(4):761. doi: 10.3390/antibiotics12040761.
本文引用的文献
1
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会关于治疗产超广谱β-内酰胺酶肠杆菌科（ESBL-E）、碳青霉烯类耐药肠杆菌科（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的指导意见。
Clin Infect Dis. 2021 Apr 8;72(7):1109-1116. doi: 10.1093/cid/ciab295.
2
The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.雷巴他定/亚胺培南/西司他丁在日本复杂性腹腔内感染或复杂性尿路感染患者中的安全性和有效性：一项多中心、开放标签、非对照的 3 期研究。
J Infect Chemother. 2021 Feb;27(2):262-270. doi: 10.1016/j.jiac.2020.09.032. Epub 2020 Nov 13.
3
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).一项比较亚胺培南/西司他丁/雷巴他定与哌拉西林/他唑巴坦治疗成人医院获得性或呼吸机相关性细菌性肺炎疗效和安全性的随机、双盲、多中心试验（RESTORE-IMI 2 研究）。
Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803.
4
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.RESTORE-IMI 1 研究：一项比较亚胺培南/雷巴他定与多黏菌素 E 联合亚胺培南治疗对亚胺培南耐药的细菌感染患者的疗效和安全性的多中心、随机、双盲试验。
Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. doi: 10.1093/cid/ciz530.
5
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.评价亚胺培南与雷巴他定联合应用对铜绿假单胞菌活性的体外研究。
BMC Microbiol. 2019 Jul 4;19(1):150. doi: 10.1186/s12866-019-1522-7.
6
Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.雷巴他定是一种有效的 KPC-2 酶抑制剂，可恢复产 KPC 肠杆菌科细菌对亚胺培南的敏感性。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00174-18. Print 2018 Jun.
7
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.美罗培南和瓦博巴坦：加强对抗碳青霉烯类耐药肠杆菌科细菌的战斗。
Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28.
8
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.亚胺培南-西司他丁钠和美罗培南-法硼巴坦：两种新型碳青霉烯-β-内酰胺酶抑制剂复方制剂。
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
9
Carbapenem-Resistant Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials.耐碳青霉烯类感染：一项回顾性研究系列的结果及对前瞻性临床试验设计的启示
Open Forum Infect Dis. 2017 Jun 1;4(2):ofx063. doi: 10.1093/ofid/ofx063. eCollection 2017 Spring.
10
Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.治疗感染碳青霉烯类耐药肠杆菌科细菌的危重症患者时的药效学和药代动力学考虑因素。
Virulence. 2017 May 19;8(4):440-452. doi: 10.1080/21505594.2016.1221021. Epub 2016 Aug 9.
Zotero 插件